Q3 EPS Estimate for NRx Pharmaceuticals Reduced by Analyst

Posted by Brian Himes on Oct 8th, 2026

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) – Stock analysts at Ascendiant Capital Markets cut their Q3 2026 earnings per share estimates for shares of NRx Pharmaceuticals in a research report issued to clients and investors on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings of ($0.15) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.80) per share. Ascendiant Capital Markets also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.35) EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Zacks Research lowered shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 26th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, September 14th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th. Finally, UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $34.50.

Read Our Latest Report on NRx Pharmaceuticals

NRx Pharmaceuticals Stock Down 1.4%

NRx Pharmaceuticals stock opened at $2.90 on Tuesday. The stock has a 50-day simple moving average of $3.29 and a 200 day simple moving average of $3.34. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The stock has a market capitalization of $125.57 million, a price-to-earnings ratio of -5.27 and a beta of 2.07.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC boosted its stake in NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the second quarter valued at approximately $54,000. Finally, AdvisorShares Investments LLC increased its stake in NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after purchasing an additional 92,463 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

Key Headlines Impacting NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

Positive Sentiment: NRx Pharmaceuticals secured a contract from the Defense Advanced Research Projects Agency (DARPA) to support a clinical trial evaluating its depression treatment, along with an $11.2 million award. The non-dilutive funding could extend the company’s cash runway, advance development of its pipeline and improve the prospects for its depression program. NRx secures DARPA contract for depression trial and $11.2 million award
Negative Sentiment: Ascendiant Capital Markets reduced its NRx earnings outlook across multiple periods. The firm lowered its Q3 2026 EPS forecast to a loss of $0.15 from a loss of $0.08 and cut its Q4 2026 estimate to a loss of $0.17 from a loss of $0.03. It now expects a full-year 2026 loss of $0.80 per share, compared with its previous estimate of a $0.36 loss. Q3 EPS estimate for NRx Pharmaceuticals lowered by analyst
Negative Sentiment: The analyst also cut its FY2027 EPS forecast to a loss of $0.35 from expected earnings of $0.50, while reducing estimates for Q1 through Q3 2027. Although a $0.05-per-share profit is projected for Q4 2027, the broader revisions suggest a slower path to profitability and may weigh on NRXP until the company demonstrates stronger revenue growth and operating performance.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations.

NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.